Medical Care

Global Mitogen-Activated Protein Kinase Inhibitors Market Research Report 2025

The global market for Mitogen-Activated Protein Kinase Inhibitors was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The mitogen-activated protein kinase (MAPK) family is a class of serine/threonine protein kinases that can transduce extracellular signals to the cell and nucleus through a conserved three-level cascade reaction (MAPKKK -MAPKK-MAPK) activates transcription factors that regulate gene expression. This pathway exists in most cells and is related to a variety of cell functions, and can participate in various physiological processes such as cell movement, apoptosis, differentiation, growth and proliferation.
North American market for Mitogen-Activated Protein Kinase Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Mitogen-Activated Protein Kinase Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Mitogen-Activated Protein Kinase Inhibitors in Colon Cancer is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Mitogen-Activated Protein Kinase Inhibitors include GEn1E Lifesciences Inc, F. Hoffmann-La Roche Ltd, Lilly, AstraZeneca, Merck & Co., Inc, HepaRegeniX GmbH, GSK plc, Mereo Biopharma Group PLC, Kura Oncology, Inc, eFFECTOR Therapeutics, Inc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Mitogen-Activated Protein Kinase Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mitogen-Activated Protein Kinase Inhibitors.
The Mitogen-Activated Protein Kinase Inhibitors market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Mitogen-Activated Protein Kinase Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Mitogen-Activated Protein Kinase Inhibitors companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GEn1E Lifesciences Inc
F. Hoffmann-La Roche Ltd
Lilly
AstraZeneca
Merck & Co., Inc
HepaRegeniX GmbH
GSK plc
Mereo Biopharma Group PLC
Kura Oncology, Inc
eFFECTOR Therapeutics, Inc
Selleck
Segment by Type
Extracellular Signal-Regulated Kinase Signaling Pathway
C-Jun N-Terminal Kinase/Stress-Activated Protein Signaling Pathway
P38 MAPK Signaling Pathway
ERK5/Macromitogen-Activated Protein Kinase Signaling Pathway
Segment by Application
Colon Cancer
Acute Myelogenous Leukemia
Malignant Melanoma
Pancreatic Cancer
Breast Cancer
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Mitogen-Activated Protein Kinase Inhibitors company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Mitogen-Activated Protein Kinase Inhibitors Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Extracellular Signal-Regulated Kinase Signaling Pathway
1.2.3 C-Jun N-Terminal Kinase/Stress-Activated Protein Signaling Pathway
1.2.4 P38 MAPK Signaling Pathway
1.2.5 ERK5/Macromitogen-Activated Protein Kinase Signaling Pathway
1.3 Market by Application
1.3.1 Global Mitogen-Activated Protein Kinase Inhibitors Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Colon Cancer
1.3.3 Acute Myelogenous Leukemia
1.3.4 Malignant Melanoma
1.3.5 Pancreatic Cancer
1.3.6 Breast Cancer
1.3.7 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Mitogen-Activated Protein Kinase Inhibitors Market Perspective (2020-2031)
2.2 Global Mitogen-Activated Protein Kinase Inhibitors Growth Trends by Region
2.2.1 Global Mitogen-Activated Protein Kinase Inhibitors Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Mitogen-Activated Protein Kinase Inhibitors Historic Market Size by Region (2020-2025)
2.2.3 Mitogen-Activated Protein Kinase Inhibitors Forecasted Market Size by Region (2026-2031)
2.3 Mitogen-Activated Protein Kinase Inhibitors Market Dynamics
2.3.1 Mitogen-Activated Protein Kinase Inhibitors Industry Trends
2.3.2 Mitogen-Activated Protein Kinase Inhibitors Market Drivers
2.3.3 Mitogen-Activated Protein Kinase Inhibitors Market Challenges
2.3.4 Mitogen-Activated Protein Kinase Inhibitors Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Mitogen-Activated Protein Kinase Inhibitors Players by Revenue
3.1.1 Global Top Mitogen-Activated Protein Kinase Inhibitors Players by Revenue (2020-2025)
3.1.2 Global Mitogen-Activated Protein Kinase Inhibitors Revenue Market Share by Players (2020-2025)
3.2 Global Mitogen-Activated Protein Kinase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Mitogen-Activated Protein Kinase Inhibitors Revenue
3.4 Global Mitogen-Activated Protein Kinase Inhibitors Market Concentration Ratio
3.4.1 Global Mitogen-Activated Protein Kinase Inhibitors Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Mitogen-Activated Protein Kinase Inhibitors Revenue in 2024
3.5 Global Key Players of Mitogen-Activated Protein Kinase Inhibitors Head office and Area Served
3.6 Global Key Players of Mitogen-Activated Protein Kinase Inhibitors, Product and Application
3.7 Global Key Players of Mitogen-Activated Protein Kinase Inhibitors, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Mitogen-Activated Protein Kinase Inhibitors Breakdown Data by Type
4.1 Global Mitogen-Activated Protein Kinase Inhibitors Historic Market Size by Type (2020-2025)
4.2 Global Mitogen-Activated Protein Kinase Inhibitors Forecasted Market Size by Type (2026-2031)
5 Mitogen-Activated Protein Kinase Inhibitors Breakdown Data by Application
5.1 Global Mitogen-Activated Protein Kinase Inhibitors Historic Market Size by Application (2020-2025)
5.2 Global Mitogen-Activated Protein Kinase Inhibitors Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Mitogen-Activated Protein Kinase Inhibitors Market Size (2020-2031)
6.2 North America Mitogen-Activated Protein Kinase Inhibitors Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Mitogen-Activated Protein Kinase Inhibitors Market Size by Country (2020-2025)
6.4 North America Mitogen-Activated Protein Kinase Inhibitors Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Mitogen-Activated Protein Kinase Inhibitors Market Size (2020-2031)
7.2 Europe Mitogen-Activated Protein Kinase Inhibitors Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Mitogen-Activated Protein Kinase Inhibitors Market Size by Country (2020-2025)
7.4 Europe Mitogen-Activated Protein Kinase Inhibitors Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Mitogen-Activated Protein Kinase Inhibitors Market Size (2020-2031)
8.2 Asia-Pacific Mitogen-Activated Protein Kinase Inhibitors Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Mitogen-Activated Protein Kinase Inhibitors Market Size by Region (2020-2025)
8.4 Asia-Pacific Mitogen-Activated Protein Kinase Inhibitors Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Mitogen-Activated Protein Kinase Inhibitors Market Size (2020-2031)
9.2 Latin America Mitogen-Activated Protein Kinase Inhibitors Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Mitogen-Activated Protein Kinase Inhibitors Market Size by Country (2020-2025)
9.4 Latin America Mitogen-Activated Protein Kinase Inhibitors Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Mitogen-Activated Protein Kinase Inhibitors Market Size (2020-2031)
10.2 Middle East & Africa Mitogen-Activated Protein Kinase Inhibitors Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Mitogen-Activated Protein Kinase Inhibitors Market Size by Country (2020-2025)
10.4 Middle East & Africa Mitogen-Activated Protein Kinase Inhibitors Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GEn1E Lifesciences Inc
11.1.1 GEn1E Lifesciences Inc Company Details
11.1.2 GEn1E Lifesciences Inc Business Overview
11.1.3 GEn1E Lifesciences Inc Mitogen-Activated Protein Kinase Inhibitors Introduction
11.1.4 GEn1E Lifesciences Inc Revenue in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025)
11.1.5 GEn1E Lifesciences Inc Recent Development
11.2 F. Hoffmann-La Roche Ltd
11.2.1 F. Hoffmann-La Roche Ltd Company Details
11.2.2 F. Hoffmann-La Roche Ltd Business Overview
11.2.3 F. Hoffmann-La Roche Ltd Mitogen-Activated Protein Kinase Inhibitors Introduction
11.2.4 F. Hoffmann-La Roche Ltd Revenue in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025)
11.2.5 F. Hoffmann-La Roche Ltd Recent Development
11.3 Lilly
11.3.1 Lilly Company Details
11.3.2 Lilly Business Overview
11.3.3 Lilly Mitogen-Activated Protein Kinase Inhibitors Introduction
11.3.4 Lilly Revenue in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025)
11.3.5 Lilly Recent Development
11.4 AstraZeneca
11.4.1 AstraZeneca Company Details
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Mitogen-Activated Protein Kinase Inhibitors Introduction
11.4.4 AstraZeneca Revenue in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025)
11.4.5 AstraZeneca Recent Development
11.5 Merck & Co., Inc
11.5.1 Merck & Co., Inc Company Details
11.5.2 Merck & Co., Inc Business Overview
11.5.3 Merck & Co., Inc Mitogen-Activated Protein Kinase Inhibitors Introduction
11.5.4 Merck & Co., Inc Revenue in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025)
11.5.5 Merck & Co., Inc Recent Development
11.6 HepaRegeniX GmbH
11.6.1 HepaRegeniX GmbH Company Details
11.6.2 HepaRegeniX GmbH Business Overview
11.6.3 HepaRegeniX GmbH Mitogen-Activated Protein Kinase Inhibitors Introduction
11.6.4 HepaRegeniX GmbH Revenue in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025)
11.6.5 HepaRegeniX GmbH Recent Development
11.7 GSK plc
11.7.1 GSK plc Company Details
11.7.2 GSK plc Business Overview
11.7.3 GSK plc Mitogen-Activated Protein Kinase Inhibitors Introduction
11.7.4 GSK plc Revenue in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025)
11.7.5 GSK plc Recent Development
11.8 Mereo Biopharma Group PLC
11.8.1 Mereo Biopharma Group PLC Company Details
11.8.2 Mereo Biopharma Group PLC Business Overview
11.8.3 Mereo Biopharma Group PLC Mitogen-Activated Protein Kinase Inhibitors Introduction
11.8.4 Mereo Biopharma Group PLC Revenue in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025)
11.8.5 Mereo Biopharma Group PLC Recent Development
11.9 Kura Oncology, Inc
11.9.1 Kura Oncology, Inc Company Details
11.9.2 Kura Oncology, Inc Business Overview
11.9.3 Kura Oncology, Inc Mitogen-Activated Protein Kinase Inhibitors Introduction
11.9.4 Kura Oncology, Inc Revenue in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025)
11.9.5 Kura Oncology, Inc Recent Development
11.10 eFFECTOR Therapeutics, Inc
11.10.1 eFFECTOR Therapeutics, Inc Company Details
11.10.2 eFFECTOR Therapeutics, Inc Business Overview
11.10.3 eFFECTOR Therapeutics, Inc Mitogen-Activated Protein Kinase Inhibitors Introduction
11.10.4 eFFECTOR Therapeutics, Inc Revenue in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025)
11.10.5 eFFECTOR Therapeutics, Inc Recent Development
11.11 Selleck
11.11.1 Selleck Company Details
11.11.2 Selleck Business Overview
11.11.3 Selleck Mitogen-Activated Protein Kinase Inhibitors Introduction
11.11.4 Selleck Revenue in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025)
11.11.5 Selleck Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Mitogen-Activated Protein Kinase Inhibitors Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Extracellular Signal-Regulated Kinase Signaling Pathway
Table 3. Key Players of C-Jun N-Terminal Kinase/Stress-Activated Protein Signaling Pathway
Table 4. Key Players of P38 MAPK Signaling Pathway
Table 5. Key Players of ERK5/Macromitogen-Activated Protein Kinase Signaling Pathway
Table 6. Global Mitogen-Activated Protein Kinase Inhibitors Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Mitogen-Activated Protein Kinase Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Mitogen-Activated Protein Kinase Inhibitors Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Mitogen-Activated Protein Kinase Inhibitors Market Share by Region (2020-2025)
Table 10. Global Mitogen-Activated Protein Kinase Inhibitors Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Mitogen-Activated Protein Kinase Inhibitors Market Share by Region (2026-2031)
Table 12. Mitogen-Activated Protein Kinase Inhibitors Market Trends
Table 13. Mitogen-Activated Protein Kinase Inhibitors Market Drivers
Table 14. Mitogen-Activated Protein Kinase Inhibitors Market Challenges
Table 15. Mitogen-Activated Protein Kinase Inhibitors Market Restraints
Table 16. Global Mitogen-Activated Protein Kinase Inhibitors Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Mitogen-Activated Protein Kinase Inhibitors Market Share by Players (2020-2025)
Table 18. Global Top Mitogen-Activated Protein Kinase Inhibitors Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mitogen-Activated Protein Kinase Inhibitors as of 2024)
Table 19. Ranking of Global Top Mitogen-Activated Protein Kinase Inhibitors Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Mitogen-Activated Protein Kinase Inhibitors Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Mitogen-Activated Protein Kinase Inhibitors, Headquarters and Area Served
Table 22. Global Key Players of Mitogen-Activated Protein Kinase Inhibitors, Product and Application
Table 23. Global Key Players of Mitogen-Activated Protein Kinase Inhibitors, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Mitogen-Activated Protein Kinase Inhibitors Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Mitogen-Activated Protein Kinase Inhibitors Revenue Market Share by Type (2020-2025)
Table 27. Global Mitogen-Activated Protein Kinase Inhibitors Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Mitogen-Activated Protein Kinase Inhibitors Revenue Market Share by Type (2026-2031)
Table 29. Global Mitogen-Activated Protein Kinase Inhibitors Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Mitogen-Activated Protein Kinase Inhibitors Revenue Market Share by Application (2020-2025)
Table 31. Global Mitogen-Activated Protein Kinase Inhibitors Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Mitogen-Activated Protein Kinase Inhibitors Revenue Market Share by Application (2026-2031)
Table 33. North America Mitogen-Activated Protein Kinase Inhibitors Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Mitogen-Activated Protein Kinase Inhibitors Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Mitogen-Activated Protein Kinase Inhibitors Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Mitogen-Activated Protein Kinase Inhibitors Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Mitogen-Activated Protein Kinase Inhibitors Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Mitogen-Activated Protein Kinase Inhibitors Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Mitogen-Activated Protein Kinase Inhibitors Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Mitogen-Activated Protein Kinase Inhibitors Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Mitogen-Activated Protein Kinase Inhibitors Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Mitogen-Activated Protein Kinase Inhibitors Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Mitogen-Activated Protein Kinase Inhibitors Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Mitogen-Activated Protein Kinase Inhibitors Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Mitogen-Activated Protein Kinase Inhibitors Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Mitogen-Activated Protein Kinase Inhibitors Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Mitogen-Activated Protein Kinase Inhibitors Market Size by Country (2026-2031) & (US$ Million)
Table 48. GEn1E Lifesciences Inc Company Details
Table 49. GEn1E Lifesciences Inc Business Overview
Table 50. GEn1E Lifesciences Inc Mitogen-Activated Protein Kinase Inhibitors Product
Table 51. GEn1E Lifesciences Inc Revenue in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025) & (US$ Million)
Table 52. GEn1E Lifesciences Inc Recent Development
Table 53. F. Hoffmann-La Roche Ltd Company Details
Table 54. F. Hoffmann-La Roche Ltd Business Overview
Table 55. F. Hoffmann-La Roche Ltd Mitogen-Activated Protein Kinase Inhibitors Product
Table 56. F. Hoffmann-La Roche Ltd Revenue in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025) & (US$ Million)
Table 57. F. Hoffmann-La Roche Ltd Recent Development
Table 58. Lilly Company Details
Table 59. Lilly Business Overview
Table 60. Lilly Mitogen-Activated Protein Kinase Inhibitors Product
Table 61. Lilly Revenue in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025) & (US$ Million)
Table 62. Lilly Recent Development
Table 63. AstraZeneca Company Details
Table 64. AstraZeneca Business Overview
Table 65. AstraZeneca Mitogen-Activated Protein Kinase Inhibitors Product
Table 66. AstraZeneca Revenue in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025) & (US$ Million)
Table 67. AstraZeneca Recent Development
Table 68. Merck & Co., Inc Company Details
Table 69. Merck & Co., Inc Business Overview
Table 70. Merck & Co., Inc Mitogen-Activated Protein Kinase Inhibitors Product
Table 71. Merck & Co., Inc Revenue in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025) & (US$ Million)
Table 72. Merck & Co., Inc Recent Development
Table 73. HepaRegeniX GmbH Company Details
Table 74. HepaRegeniX GmbH Business Overview
Table 75. HepaRegeniX GmbH Mitogen-Activated Protein Kinase Inhibitors Product
Table 76. HepaRegeniX GmbH Revenue in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025) & (US$ Million)
Table 77. HepaRegeniX GmbH Recent Development
Table 78. GSK plc Company Details
Table 79. GSK plc Business Overview
Table 80. GSK plc Mitogen-Activated Protein Kinase Inhibitors Product
Table 81. GSK plc Revenue in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025) & (US$ Million)
Table 82. GSK plc Recent Development
Table 83. Mereo Biopharma Group PLC Company Details
Table 84. Mereo Biopharma Group PLC Business Overview
Table 85. Mereo Biopharma Group PLC Mitogen-Activated Protein Kinase Inhibitors Product
Table 86. Mereo Biopharma Group PLC Revenue in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025) & (US$ Million)
Table 87. Mereo Biopharma Group PLC Recent Development
Table 88. Kura Oncology, Inc Company Details
Table 89. Kura Oncology, Inc Business Overview
Table 90. Kura Oncology, Inc Mitogen-Activated Protein Kinase Inhibitors Product
Table 91. Kura Oncology, Inc Revenue in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025) & (US$ Million)
Table 92. Kura Oncology, Inc Recent Development
Table 93. eFFECTOR Therapeutics, Inc Company Details
Table 94. eFFECTOR Therapeutics, Inc Business Overview
Table 95. eFFECTOR Therapeutics, Inc Mitogen-Activated Protein Kinase Inhibitors Product
Table 96. eFFECTOR Therapeutics, Inc Revenue in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025) & (US$ Million)
Table 97. eFFECTOR Therapeutics, Inc Recent Development
Table 98. Selleck Company Details
Table 99. Selleck Business Overview
Table 100. Selleck Mitogen-Activated Protein Kinase Inhibitors Product
Table 101. Selleck Revenue in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025) & (US$ Million)
Table 102. Selleck Recent Development
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
Table 106. Authors List of This Report


List of Figures
Figure 1. Mitogen-Activated Protein Kinase Inhibitors Picture
Figure 2. Global Mitogen-Activated Protein Kinase Inhibitors Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Mitogen-Activated Protein Kinase Inhibitors Market Share by Type: 2024 VS 2031
Figure 4. Extracellular Signal-Regulated Kinase Signaling Pathway Features
Figure 5. C-Jun N-Terminal Kinase/Stress-Activated Protein Signaling Pathway Features
Figure 6. P38 MAPK Signaling Pathway Features
Figure 7. ERK5/Macromitogen-Activated Protein Kinase Signaling Pathway Features
Figure 8. Global Mitogen-Activated Protein Kinase Inhibitors Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Mitogen-Activated Protein Kinase Inhibitors Market Share by Application: 2024 VS 2031
Figure 10. Colon Cancer Case Studies
Figure 11. Acute Myelogenous Leukemia Case Studies
Figure 12. Malignant Melanoma Case Studies
Figure 13. Pancreatic Cancer Case Studies
Figure 14. Breast Cancer Case Studies
Figure 15. Other Case Studies
Figure 16. Mitogen-Activated Protein Kinase Inhibitors Report Years Considered
Figure 17. Global Mitogen-Activated Protein Kinase Inhibitors Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 18. Global Mitogen-Activated Protein Kinase Inhibitors Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 19. Global Mitogen-Activated Protein Kinase Inhibitors Market Share by Region: 2024 VS 2031
Figure 20. Global Mitogen-Activated Protein Kinase Inhibitors Market Share by Players in 2024
Figure 21. Global Top Mitogen-Activated Protein Kinase Inhibitors Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mitogen-Activated Protein Kinase Inhibitors as of 2024)
Figure 22. The Top 10 and 5 Players Market Share by Mitogen-Activated Protein Kinase Inhibitors Revenue in 2024
Figure 23. North America Mitogen-Activated Protein Kinase Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. North America Mitogen-Activated Protein Kinase Inhibitors Market Share by Country (2020-2031)
Figure 25. United States Mitogen-Activated Protein Kinase Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Canada Mitogen-Activated Protein Kinase Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe Mitogen-Activated Protein Kinase Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Europe Mitogen-Activated Protein Kinase Inhibitors Market Share by Country (2020-2031)
Figure 29. Germany Mitogen-Activated Protein Kinase Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. France Mitogen-Activated Protein Kinase Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. U.K. Mitogen-Activated Protein Kinase Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Italy Mitogen-Activated Protein Kinase Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Russia Mitogen-Activated Protein Kinase Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Nordic Countries Mitogen-Activated Protein Kinase Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Mitogen-Activated Protein Kinase Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Mitogen-Activated Protein Kinase Inhibitors Market Share by Region (2020-2031)
Figure 37. China Mitogen-Activated Protein Kinase Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Japan Mitogen-Activated Protein Kinase Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. South Korea Mitogen-Activated Protein Kinase Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Southeast Asia Mitogen-Activated Protein Kinase Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. India Mitogen-Activated Protein Kinase Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Australia Mitogen-Activated Protein Kinase Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America Mitogen-Activated Protein Kinase Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Latin America Mitogen-Activated Protein Kinase Inhibitors Market Share by Country (2020-2031)
Figure 45. Mexico Mitogen-Activated Protein Kinase Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Brazil Mitogen-Activated Protein Kinase Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa Mitogen-Activated Protein Kinase Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Middle East & Africa Mitogen-Activated Protein Kinase Inhibitors Market Share by Country (2020-2031)
Figure 49. Turkey Mitogen-Activated Protein Kinase Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Saudi Arabia Mitogen-Activated Protein Kinase Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. UAE Mitogen-Activated Protein Kinase Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. GEn1E Lifesciences Inc Revenue Growth Rate in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025)
Figure 53. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025)
Figure 54. Lilly Revenue Growth Rate in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025)
Figure 55. AstraZeneca Revenue Growth Rate in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025)
Figure 56. Merck & Co., Inc Revenue Growth Rate in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025)
Figure 57. HepaRegeniX GmbH Revenue Growth Rate in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025)
Figure 58. GSK plc Revenue Growth Rate in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025)
Figure 59. Mereo Biopharma Group PLC Revenue Growth Rate in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025)
Figure 60. Kura Oncology, Inc Revenue Growth Rate in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025)
Figure 61. eFFECTOR Therapeutics, Inc Revenue Growth Rate in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025)
Figure 62. Selleck Revenue Growth Rate in Mitogen-Activated Protein Kinase Inhibitors Business (2020-2025)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies